Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations and clinical impact.

Baliakas P, Jeromin S, Iskas M, Puiggros A, Plevova K, NguyenKhac F, Davis Z, Rigolin GM, Visentin A, Xochelli A, Delgado J, Baran-Marszak F, Stalika E, Abrisqueta P, Durechova K, Papaioannou G, Eclache V, Dimou M, Iliakis T, Collado R, Doubek M, Calasanz MJ, Ruiz-Xiville N, Moreno C, Jarosova M, Leeksma AC, Panayiotidis P, Podgornik H, Cymbalista F, Anagnostopoulos A, Trentin L, Stavroyianni N, Davi F, Ghia P, Kater AP, Cuneo A, Pospisilova S, Espinet B, Athanasiadou A, Oscier D, Haferlach C, Stamatopoulos K.

Blood. 2019 Jan 2. pii: blood-2018-09-873083. doi: 10.1182/blood-2018-09-873083. [Epub ahead of print]

PMID:
30602617
2.

High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology.

Chong LC, Ben-Neriah S, Slack GW, Freeman C, Ennishi D, Mottok A, Collinge B, Abrisqueta P, Farinha P, Boyle M, Meissner B, Kridel R, Gerrie AS, Villa D, Savage KJ, Sehn LH, Siebert R, Morin RD, Gascoyne RD, Marra MA, Connors JM, Mungall AJ, Steidl C, Scott DW.

Blood Adv. 2018 Oct 23;2(20):2755-2765. doi: 10.1182/bloodadvances.2018023572.

3.

Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma.

Baptista MJ, Tapia G, Morgades M, Muncunill J, Muñoz-Marmol AM, Montoto S, Gribben JG, Calaminici M, Martinez A, Gonzalez-Farre B, Dlouhy I, González-Barca E, Terol MJ, Miralles P, Alcoceba M, Vall-Llovera F, Briones J, Abrisqueta P, Abella E, Provencio M, García-Ballesteros C, Moraleda JM, Sancho JM, Ribera JM, Mate JL, Navarro JT.

Leuk Lymphoma. 2018 Oct 15:1-5. doi: 10.1080/10428194.2018.1512711. [Epub ahead of print] No abstract available.

PMID:
30322315
4.

Posttransplant monomorphic Burkitt's lymphoma: clinical characteristics and outcome of a multicenter series.

Bobillo S, Abrisqueta P, Sánchez-González B, Giné E, Romero S, Alcoceba M, González-Barca E, González de Villambrosía S, Sancho JM, Gómez P, Bento L, Montoro J, Montes S, López A, Bosch F; Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GEL/TAMO cooperative group).

Ann Hematol. 2018 Dec;97(12):2417-2424. doi: 10.1007/s00277-018-3473-8. Epub 2018 Aug 16.

PMID:
30116871
5.

Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL.

Blanco G, Vardi A, Puiggros A, Gómez-Llonín A, Muro M, Rodríguez-Rivera M, Stalika E, Abella E, Gimeno E, López-Sánchez M, Senín A, Calvo X, Abrisqueta P, Bosch F, Ferrer A, Stamatopoulos K, Espinet B.

Oncoimmunology. 2018 Feb 20;7(6):e1432328. doi: 10.1080/2162402X.2018.1432328. eCollection 2018.

PMID:
29872562
6.

Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement.

Bobillo S, Abrisqueta P, Carpio C, Raheja P, Castellví J, Crespo M, Bosch F.

Haematologica. 2018 Feb;103(2):e92-e93. doi: 10.3324/haematol.2017.181636. Epub 2017 Dec 14. No abstract available.

7.

Observation as the initial management strategy in patients with mantle cell lymphoma.

Abrisqueta P, Scott DW, Slack GW, Steidl C, Mottok A, Gascoyne RD, Connors JM, Sehn LH, Savage KJ, Gerrie AS, Villa D.

Ann Oncol. 2017 Oct 1;28(10):2489-2495. doi: 10.1093/annonc/mdx333.

PMID:
28961827
8.

Microenvironment regulates the expression of miR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia.

Carabia J, Carpio C, Abrisqueta P, Jiménez I, Purroy N, Calpe E, Palacio C, Bosch F, Crespo M.

Sci Rep. 2017 Sep 25;7(1):12262. doi: 10.1038/s41598-017-12135-7.

9.

Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions.

Puiggros A, Collado R, Calasanz MJ, Ortega M, Ruiz-Xivillé N, Rivas-Delgado A, Luño E, González T, Navarro B, García-Malo M, Valiente A, Hernández JÁ, Ardanaz MT, Piñan MÁ, Blanco ML, Hernández-Sánchez M, Batlle-López A, Salgado R, Salido M, Ferrer A, Abrisqueta P, Gimeno E, Abella E, Ferrá C, Terol MJ, Ortuño F, Costa D, Moreno C, Carbonell F, Bosch F, Delgado J, Espinet B.

Oncotarget. 2017 Apr 21;8(33):54297-54303. doi: 10.18632/oncotarget.17350. eCollection 2017 Aug 15.

10.

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.

Vitolo U, Trněný M, Belada D, Burke JM, Carella AM, Chua N, Abrisqueta P, Demeter J, Flinn I, Hong X, Kim WS, Pinto A, Shi YK, Tatsumi Y, Oestergaard MZ, Wenger M, Fingerle-Rowson G, Catalani O, Nielsen T, Martelli M, Sehn LH.

J Clin Oncol. 2017 Nov 1;35(31):3529-3537. doi: 10.1200/JCO.2017.73.3402. Epub 2017 Aug 10.

PMID:
28796588
11.

New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies.

Scott DW, Abrisqueta P, Wright GW, Slack GW, Mottok A, Villa D, Jares P, Rauert-Wunderlich H, Royo C, Clot G, Pinyol M, Boyle M, Chan FC, Braziel RM, Chan WC, Weisenburger DD, Cook JR, Greiner TC, Fu K, Ott G, Delabie J, Smeland EB, Holte H, Jaffe ES, Steidl C, Connors JM, Gascoyne RD, Rosenwald A, Staudt LM, Campo E, Rimsza LM; Lymphoma/Leukemia Molecular Profiling Project.

J Clin Oncol. 2017 May 20;35(15):1668-1677. doi: 10.1200/JCO.2016.70.7901. Epub 2017 Mar 14.

12.

Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia.

García-Marco JA, Delgado J, Hernández-Rivas JA, Ramírez Payer Á, Loscertales Pueyo J, Jarque I, Abrisqueta P, Giraldo P, Martínez R, Yáñez L, Terol MJ, González M, Bosch F; en nombre del Grupo Español de Leucemia Linfocítica Crónica (GELLC).

Med Clin (Barc). 2017 Apr 21;148(8):381.e1-381.e9. doi: 10.1016/j.medcli.2016.12.030. Epub 2017 Feb 22. English, Spanish.

PMID:
28236475
13.

Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.

Purroy N, Carabia J, Abrisqueta P, Egia L, Aguiló M, Carpio C, Palacio C, Crespo M, Bosch F.

Oncotarget. 2017 Jan 3;8(1):742-756. doi: 10.18632/oncotarget.13557.

14.

Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations.

Blanco G, Puiggros A, Baliakas P, Athanasiadou A, García-Malo M, Collado R, Xochelli A, Rodríguez-Rivera M, Ortega M, Calasanz MJ, Luño E, Vargas M, Grau J, Martínez-Laperche C, Valiente A, Cervera J, Anagnostopoulos A, Gimeno E, Abella E, Stalika E, Hernández-Rivas JM, Ortuño FJ, Robles D, Ferrer A, Ivars D, González M, Bosch F, Abrisqueta P, Stamatopoulos K, Espinet B.

Oncotarget. 2016 Dec 6;7(49):80916-80924. doi: 10.18632/oncotarget.13106.

15.

The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial).

Montesinos P, Cabrero M, Valcárcel D, Rovira M, García-Marco JA, Loscertales J, Moreno C, Duarte R, Terol MJ, Villamor N, Abrisqueta P, Caballero D, Sanz J, Delgado J.

Bone Marrow Transplant. 2016 Oct;51(10):1404-1407. doi: 10.1038/bmt.2016.145. Epub 2016 May 23. No abstract available.

PMID:
27214073
16.

A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia.

Hernández JÁ, Hernández-Sánchez M, Rodríguez-Vicente AE, Grossmann V, Collado R, Heras C, Puiggros A, Martín AÁ, Puig N, Benito R, Robledo C, Delgado J, González T, Queizán JA, Galende J, de la Fuente I, Martín-Núñez G, Alonso JM, Abrisqueta P, Luño E, Marugán I, González-Gascón I, Bosch F, Kohlmann A, González M, Espinet B, Hernández-Rivas JM; Grupo Cooperativo Español de Citogenética Hematológica (GCECGH) and Grupo Español de Leucemia Linfática Crónica (GELLC).

PLoS One. 2015 Dec 2;10(11):e0143073. doi: 10.1371/journal.pone.0143073. eCollection 2015.

17.

Ibrutinib in CLL: 2 sides of the same coin.

Bosch F, Abrisqueta P.

Blood. 2015 Nov 5;126(19):2173-4. doi: 10.1182/blood-2015-09-670653. No abstract available.

18.

Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.

Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, Kridel R, Barry GS, Hother C, Abrisqueta P, Boyle M, Meissner B, Telenius A, Savage KJ, Sehn LH, Slack GW, Steidl C, Staudt LM, Connors JM, Rimsza LM, Gascoyne RD.

J Clin Oncol. 2015 Sep 10;33(26):2848-56. doi: 10.1200/JCO.2014.60.2383. Epub 2015 Aug 3.

19.

[Importance of hepatitis B virus screening in hematological patients].

Riveiro-Barciela M, Artaza G, Abrisqueta P, Bosch F, Buti M.

Gastroenterol Hepatol. 2015 Nov;38(9):563-4. doi: 10.1016/j.gastrohep.2015.03.004. Epub 2015 Apr 14. Spanish. No abstract available.

PMID:
25888287
20.

Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma.

Brown JR, Davids MS, Rodon J, Abrisqueta P, Kasar SN, Lager J, Jiang J, Egile C, Awan FT.

Clin Cancer Res. 2015 Jul 15;21(14):3160-9. doi: 10.1158/1078-0432.CCR-14-3262. Epub 2015 Apr 3.

22.

Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma.

Papadopoulos KP, Egile C, Ruiz-Soto R, Jiang J, Shi W, Bentzien F, Rasco D, Abrisqueta P, Vose JM, Tabernero J.

Leuk Lymphoma. 2015 Jun;56(6):1763-70. doi: 10.3109/10428194.2014.974040. Epub 2014 Nov 19.

PMID:
25300944
23.

Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein.

Purroy N, Abrisqueta P, Carabia J, Carpio C, Calpe E, Palacio C, Castellví J, Crespo M, Bosch F.

Leukemia. 2014 Oct;28(10):1993-2004. doi: 10.1038/leu.2014.96. Epub 2014 Mar 12.

PMID:
24618734
24.

Analysis of the IGHV region in Burkitt's lymphomas supports a germinal center origin and a role for superantigens in lymphomagenesis.

Baptista MJ, Calpe E, Fernandez E, Colomo L, Cardesa-Salzmann TM, Abrisqueta P, Bosch F, Crespo M.

Leuk Res. 2014 Apr;38(4):509-15. doi: 10.1016/j.leukres.2014.01.001. Epub 2014 Jan 13.

PMID:
24480549
25.

Distinction between asymptomatic monoclonal B-cell lymphocytosis with cyclin D1 overexpression and mantle cell lymphoma: from molecular profiling to flow cytometry.

Espinet B, Ferrer A, Bellosillo B, Nonell L, Salar A, Fernández-Rodríguez C, Puigdecanet E, Gimeno J, Garcia-Garcia M, Vela MC, Luño E, Collado R, Navarro JT, de la Banda E, Abrisqueta P, Arenillas L, Serrano C, Lloreta J, Miñana B, Cerutti A, Florensa L, Orfao A, Sanz F, Solé F, Dominguez-Sola D, Serrano S.

Clin Cancer Res. 2014 Feb 15;20(4):1007-19. doi: 10.1158/1078-0432.CCR-13-1077. Epub 2013 Dec 18.

26.

ZAP-70 promotes the infiltration of malignant B-lymphocytes into the bone marrow by enhancing signaling and migration after CXCR4 stimulation.

Calpe E, Purroy N, Carpio C, Abrisqueta P, Carabia J, Palacio C, Castellví J, Crespo M, Bosch F.

PLoS One. 2013 Dec 3;8(12):e81221. doi: 10.1371/journal.pone.0081221. eCollection 2013.

27.

Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.

Abrisqueta P, Villamor N, Terol MJ, González-Barca E, González M, Ferrà C, Abella E, Delgado J, García-Marco JA, González Y, Carbonell F, Ferrer S, Monzó E, Jarque I, Muntañola A, Constants M, Escoda L, Calvo X, Bobillo S, Montoro JB, Montserrat E, Bosch F.

Blood. 2013 Dec 5;122(24):3951-9. doi: 10.1182/blood-2013-05-502773. Epub 2013 Oct 11.

28.

Biallelic losses of 13q do not confer a poorer outcome in chronic lymphocytic leukaemia: analysis of 627 patients with isolated 13q deletion.

Puiggros A, Delgado J, Rodriguez-Vicente A, Collado R, Aventín A, Luño E, Grau J, Hernandez JÁ, Marugán I, Ardanaz M, González T, Valiente A, Osma M, Calasanz MJ, Sanzo C, Carrió A, Ortega M, Santacruz R, Abrisqueta P, Abella E, Bosch F, Carbonell F, Solé F, Hernández JM, Espinet B; Grupo Cooperativo Español de Citogenética Hematológica (GCECGH) and Grupo Español de Leucemia Linfática Crónica (GELLC).

Br J Haematol. 2013 Oct;163(1):47-54. doi: 10.1111/bjh.12479. Epub 2013 Jul 19.

PMID:
23869550
29.

NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome.

Villamor N, Conde L, Martínez-Trillos A, Cazorla M, Navarro A, Beà S, López C, Colomer D, Pinyol M, Aymerich M, Rozman M, Abrisqueta P, Baumann T, Delgado J, Giné E, González-Díaz M, Hernández JM, Colado E, Payer AR, Rayon C, Navarro B, José Terol M, Bosch F, Quesada V, Puente XS, López-Otín C, Jares P, Pereira A, Campo E, López-Guillermo A.

Leukemia. 2013 Apr;27(5):1100-6. doi: 10.1038/leu.2012.357. Epub 2012 Dec 6.

PMID:
23295735
30.

Differential gene expression profile associated to apoptosis induced by dexamethasone in CLL cells according to IGHV/ZAP-70 status.

Baptista MJ, Muntañola A, Calpe E, Abrisqueta P, Salamero O, Fernández E, Codony C, Giné E, Kalko SG, Crespo M, Bosch F.

Clin Cancer Res. 2012 Nov 1;18(21):5924-33. doi: 10.1158/1078-0432.CCR-11-2771. Epub 2012 Sep 10.

31.

Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results.

Delgado J, Espinet B, Oliveira AC, Abrisqueta P, de la Serna J, Collado R, Loscertales J, Lopez M, Hernandez-Rivas JA, Ferra C, Ramirez A, Roncero JM, Lopez C, Aventin A, Puiggros A, Abella E, Carbonell F, Costa D, Carrio A, Gonzalez M; Grupo Español de Leucemia Linfatica Cronica; Grupo Español de Citogenetica Hematologica.

Br J Haematol. 2012 Apr;157(1):67-74. doi: 10.1111/j.1365-2141.2011.09000.x. Epub 2012 Jan 9.

PMID:
22224845
32.

ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation.

Calpe E, Codony C, Baptista MJ, Abrisqueta P, Carpio C, Purroy N, Bosch F, Crespo M.

Blood. 2011 Oct 20;118(16):4401-10. doi: 10.1182/blood-2011-01-333682. Epub 2011 Aug 24.

33.

Personalizing treatment for chronic lymphocytic leukemia.

Abrisqueta P, Crespo M, Bosch F.

Expert Rev Hematol. 2011 Feb;4(1):27-35. doi: 10.1586/ehm.10.84.

PMID:
21322776
34.

Selection and viral load kinetics of an oseltamivir-resistant pandemic influenza A (H1N1) virus in an immunocompromised patient during treatment with neuraminidase inhibitors.

Antón A, López-Iglesias AA, Tórtola T, Ruiz-Camps I, Abrisqueta P, Llopart L, Marcos MÁ, Martínez MJ, Tudó G, Bosch F, Pahissa A, de Anta MT, Pumarola T.

Diagn Microbiol Infect Dis. 2010 Nov;68(3):214-9. doi: 10.1016/j.diagmicrobio.2010.08.003.

PMID:
20955912
35.

Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era.

Gutiérrez-García G, Colomo L, Villamor N, Arenillas L, Martínez A, Cardesa T, García-Herrera A, Setoain X, Rodríguez S, Ghita G, Abrisqueta P, Giné E, Bosch F, Campo E, Montserrat E, López-Guillermo A.

Leuk Lymphoma. 2010 Jul;51(7):1225-32. doi: 10.3109/10428194.2010.483301.

PMID:
20497002
36.

Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior.

Giné E, Martinez A, Villamor N, López-Guillermo A, Camos M, Martinez D, Esteve J, Calvo X, Muntañola A, Abrisqueta P, Rozman M, Rozman C, Bosch F, Campo E, Montserrat E.

Haematologica. 2010 Sep;95(9):1526-33. doi: 10.3324/haematol.2010.022277. Epub 2010 Apr 26.

37.

Histological transformation of follicular lymphoma after treatment: a case evaluated with PET/CT.

Mena LM, Setoain X, Abrisqueta P, Rodríguez S, López-Guillermo A, Fuster D, Lafuente S, Fuertes S, Rubí S, Pons F.

Clin Nucl Med. 2009 Nov;34(11):793-4. doi: 10.1097/RLU.0b013e3181b7d6f4. No abstract available.

PMID:
19851178
38.

Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.

Bosch F, Abrisqueta P, Villamor N, Terol MJ, González-Barca E, Ferra C, González Diaz M, Abella E, Delgado J, Carbonell F, García Marco JA, Escoda L, Ferrer S, Monzó E, González Y, Estany C, Jarque I, Salamero O, Muntañola A, Montserrat E.

J Clin Oncol. 2009 Sep 20;27(27):4578-84. doi: 10.1200/JCO.2009.22.0442. Epub 2009 Aug 24.

PMID:
19704063
39.

Gene expression profiling in chronic lymphocytic leukaemia.

Codony C, Crespo M, Abrisqueta P, Montserrat E, Bosch F.

Best Pract Res Clin Haematol. 2009 Jun;22(2):211-22. doi: 10.1016/j.beha.2009.05.006. Review.

PMID:
19698929
40.

Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience.

Abrisqueta P, Pereira A, Rozman C, Aymerich M, Giné E, Moreno C, Muntañola A, Rozman M, Villamor N, Hodgson K, Campo E, Bosch F, Montserrat E.

Blood. 2009 Sep 3;114(10):2044-50. doi: 10.1182/blood-2009-04-214346. Epub 2009 Jun 24.

41.

Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue.

Hartmann E, Fernàndez V, Moreno V, Valls J, Hernández L, Bosch F, Abrisqueta P, Klapper W, Dreyling M, Hoster E, Müller-Hermelink HK, Ott G, Rosenwald A, Campo E.

J Clin Oncol. 2008 Oct 20;26(30):4966-72. doi: 10.1200/JCO.2007.12.0410. Epub 2008 Jul 7.

PMID:
18606985
42.

MicroRNA expression profiling in classic Hodgkin lymphoma.

Navarro A, Gaya A, Martinez A, Urbano-Ispizua A, Pons A, Balagué O, Gel B, Abrisqueta P, Lopez-Guillermo A, Artells R, Montserrat E, Monzo M.

Blood. 2008 Mar 1;111(5):2825-32. Epub 2007 Dec 18.

43.

[Autologous haematopoietic stem cell transplantation in POEMS syndrome: results in 4 cases].

Abrisqueta P, Rovira M, Cibeira MT, Vallansot R, Gutiérrez G, Bladé J, Carreras E, Montserrat E.

Med Clin (Barc). 2007 Oct 27;129(15):578-81. Spanish.

PMID:
17988616
44.

Abdominal computed tomography predicts progression in patients with Rai stage 0 chronic lymphocytic leukemia.

Muntañola A, Bosch F, Arguis P, Arellano-Rodrigo E, Ayuso C, Giné E, Crespo M, Abrisqueta P, Moreno C, Cobo F, López-Guillermo A, Montserrat E.

J Clin Oncol. 2007 Apr 20;25(12):1576-80. Epub 2007 Mar 12.

PMID:
17353549

Supplemental Content

Loading ...
Support Center